ACS And GI Bleeding PPI Indication Tool

Clinical calculation support · Verify results before clinical use

Gastrointestinal bleeding risk assessment

Select the patient's antithrombotic treatment and gastrointestinal risk factors.

Clinical aid
1
Dual antiplatelet therapy (DAPT)

For example, aspirin plus a P2Y12 inhibitor.

2
Oral anticoagulant therapy

For example, a vitamin K antagonist or a direct oral anticoagulant.

3
Previous gastrointestinal bleeding or peptic ulcer

Includes a documented history of gastrointestinal ulcer or haemorrhage.

4
Chronic NSAID or systemic corticosteroid use

Select yes if the patient regularly uses either medication.

5
Age 65 years or older

Age is considered alongside other minor risk factors.

6
Dyspepsia

Current or recurrent dyspeptic symptoms.

7
Gastro-oesophageal reflux disease (GERD)

Known or diagnosed GERD.

8
Helicobacter pylori infection

Known infection, if status is available.

9
Chronic alcohol use

Ongoing chronic alcohol consumption.

PPI
Assessment

PPI recommendation

Clinical guidance

Assessment itemSelected response

How to interpret this assessment

For patients with acute coronary syndrome (ACS), the 2025 ACC/AHA ACS guideline recommends a proton pump inhibitor (PPI) alongside dual antiplatelet therapy, oral anticoagulant therapy, or both when gastrointestinal bleeding risk is high. This tool provides a structured prompt for assessing selected risk factors; it is not a validated bleeding-risk score.

Risk-factor approach used in this tool

  • Major factors: previous gastrointestinal ulcer or haemorrhage, chronic NSAID or systemic corticosteroid use, and oral anticoagulant therapy.
  • Additional factors: age 65 years or older, dyspepsia, GERD, Helicobacter pylori infection, and chronic alcohol use. The 2023 ESC guideline lists two or more of these additional factors as a reason to consider PPI protection in patients receiving DAPT.
  • Interpretation: any major factor or at least two additional factors flags increased gastrointestinal risk for clinical review. The result does not replace assessment of the full clinical context.

Important limitations

The risk-factor grouping displayed here is a practical aid based on guideline descriptions, not a prospectively validated prediction model. The 2025 ACC/AHA recommendation is framed around high gastrointestinal bleeding risk and does not endorse this tool's questions as a formal score. Consider other clinical factors, active bleeding, drug interactions, treatment duration, and local guidance.

References

Rao SV, O'Donoghue ML, Ruel M, et al.2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151:e771–e862. doi:10.1161/CIR.0000000000001309.
Byrne RA, Rossello X, Coughlan JJ, et al.2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191.
Clinical disclaimer: This tool supports, but does not replace, clinical judgement or local protocols. It is not intended to diagnose or quantify an individual's absolute bleeding risk. Suspected or active gastrointestinal bleeding requires prompt clinical assessment. Prescribing decisions should account for the indication, potential harms, interactions, and duration of PPI therapy.